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Abstract
Dorsal hippocampal regions are involved in memory and learning processes, while ventral areas are related to emotional
and anxiety processes. Hippocampal dependent memory and behaviour alterations do not always come out in
neurodegenerative diseases at the same time. In this study we have tested the hypothesis that dorsal and ventral dentate
gyrus (DG) regions respond in a different manner to increased glycogen synthase kinase-3b (GSK3b) levels in GSK3b
transgenic mice, a genetic model of neurodegeneration. Reactive astrocytosis indicate tissue stress in dorsal DG, while
ventral area does not show that marker. These changes occurred with a significant reduction of total cell number and with a
significantly higher level of cell death in dorsal area than in ventral one as measured by fractin-positive cells. Biochemistry
analysis showed higher levels of phosphorylated GSK3b in those residues that inactivate the enzyme in hippocampal ventral
areas compared with dorsal area suggesting that the observed susceptibility is in part due to different GSK3 regulation.
Previous studies carried out with this animal model had demonstrated impairment in Morris Water Maze and Object
recognition tests point out to dorsal hippocampal atrophy. Here, we show that two tests used to evaluate emotional status,
the light–dark box and the novelty suppressed feeding test, suggest that GSK3b mice do not show any anxiety-related
disorder. Thus, our results demonstrate that in vivo overexpression of GSK3b results in dorsal but not ventral hippocampal
DG neurodegeneration and suggest that both areas do not behave in a similar manner in neurodegenerative processes.
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Introduction
GSK3 is a kinase present in most tissues and is particularly
abundant in the brain [1]. There are two isoforms of the enzyme
termed GSK3a and GSK3b [1]. GSK3 is known to participate in
multiple signaling pathways coupled to receptors for a variety of
signaling molecules such as insulin or wnt among many others [2].
Aberrantly increased GSK3 activity is believed to play a key role
in the pathogenesis of chronic metabolic disorders like type-II
diabetes [3], as well as of CNS conditions such as bipolar mood
disorder [4], schizophrenia [5], diseases like Huntington’s disease
[6], frontotemporal dementia with parkinsonism linked to
chromosome 17 [7] and Alzheimer disease [8]. With regard to
GSK3 and neurodegeneration, increased GSK3 activity has been
reported to result in neuronal apoptosis and GSK3 inhibitors have
been shown to exert antiapoptotic and neuroprotective effects in
many different cell and mouse models [9,10,11]. Accordingly,
potent and specific GSK3 inhibitors are currently under
development [12,13,14].
Recent evidences have established that there are differences
among dorsal and ventral hippocampal areas, at least in rodent
[15]. All these differences are associated with functional special-
ization, as studies with lesions in dorsal or ventral hippocampus
demonstrate [16]. Thus, dorsal regions are involved mainly in
memory and learning processes, while ventral areas are related
with anxiety, affective or emotional processes [17]. That
regionalized processes correlate at genetic and cellular levels,
showing that DG is not uniform and that there exist a regionalized
specialization [15]. Those studies can be likely translated to
human. Thus, the dorsal hippocampus corresponds to the
posterior hippocampus in primates, while the ventral correspond
to the anterior hippocampus in primates [15].
Here, we have first analyzed GSK3b levels in both DG areas in
wild-type mice and explored the effect of GSK3b overexpression
in both dorsal DG (dDG) and ventral DG (vDG) in a mouse
model with increased GSK3b levels in those hippocampal areas
[18]. This animal model exhibits a memory deficit [19,20] and
impaired synaptic plasticity [21]. We demonstrate that ventral
hippocampus withstands a neurodegenerative signal as an
increase in GSK3b levels better than dorsal hippocampus. In
good agreement, evaluation of anxiety-related tests shows a
normal behaviour.
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Animals and tissue processing
Animal care. Mice were obtained from the Centro de
Biologıı ´a Molecular and treated following the guidelines of
Council of Europe Convention ETS123, recently revised as
indicated in the Directive 86/609/EEC. Animal experiments were
performed under protocols (P15/P16/P18/P22) approved by the
Centro de Biologı ´a Molecular Severo Ochoa Institutional Animal
Care and Utilization Committee (CEEA-CBM), Madrid, Spain.
GSK3b mice were generated as described previously [18].
Briefly, GSK3b mice were bred by crossing TetO mice (carrying
the bi-direccional tet-responsive promoter followed by the GSK3b
and b-galactosidase cDNAs, one in each direction) with Cam-
KIIa-tTA mice. The dual transgenic mice were designated
GSK3b, and they overexpress GSK3b in the cortex and
hippocampus. Transgenic mice as well as wt mice (C57BL/6)
were bred at the Centro de Biologı ´a Molecular ‘‘Severo Ochoa’’ (Madrid,
Spain) and the mice were kept on a normal light-dark cycle
(12 hours light/12 hours dark), with free access to food and water.
Tissue processing. Animals were killed and the brain was
removed, post-fixed overnight in 4% PFA and 30 mm sagittal
sections were obtained on a cryostat.
Volumetric measurement of dentate gyrus atrophy
For volumetric measurement, thionine stained section areas of
dentate gyrus were delineated and measured by means of
Methamorph image-analysis system. The total volume (mm3) of
each granule cell layer was achieved by integration of areas (mm2)
with the distance between each sagital plane (mm). The points for
integration were 0.36 mm (Fig 104 of the atlas of Paxinos and
Franklin [22]) and 3.00 mm (Fig 126 of the same atlas) with
respect to the midline. In those sections were dentate gyrus is not
divided in two areas, dorsal and ventral areas were measured
taking into account the middle point.
Western blot analysis
Brains were quickly dissected on an ice-cold plate. Hippocam-
pus was isolated and horizontally cut in two equals halves, the
dorsal and the ventral hippocampus. Extracts for Western blot
analysis were prepared by homogenizing the dorsal and ventral
hippocampus from 2 months-old wildtype and transgenic animals
in ice-cold extraction buffer consisting of 50 mM Tris HCl,
pH 7.4, 150 mM NaCl, 1% NP-40, 1 mM sodium orthovanadate,
1 mM EDTA, a protease inhibitor cocktail (Roche) and 1 mM
Okadaic acid (phosphatase inhibitor). The samples were homog-
enized and protein content was determined by Bradford. Thirty
micrograms of total protein were electrophoresed on 10% SDS-
polyacrylamide gel and transferred to a nitrocellulose membrane
(Schleicher & Schuell, Keene, NH). The experiments were
performed using the following primary monoclonal antibodies:
anti-GSK3b (1/1000) (BD Transduction Laboratories), anti-p21/
9- GSK3a/b (1/500) (Cell Signalling), anti-Akt (1/1000) and anti-
phospho-Akt (Ser473) (1/1000) (both from Cell Signalling) and
anti-actin (1/5000) (Sigma). The following anti-tau antibodies
were used: PHF-1 (1/200, a kind gift from Dr. Davis) reacts with
tau when serines 396 and 404 are phosphorylated [23] and 7.51
(1/200; a kind gift from Dr Wischik) which recognizes segments of
the last two repeats within the microtubule binding domain of tau
in a phosphorylation-independent manner [24]. The filters were
incubated with the antibody at 4uC overnight in 5% nonfat dried
milk. Secondary goat anti-mouse and anti-rabbit antibodies (1/
1000; Invitrogen, San Diego, CA) and ECL detection reagents
(Amersham Biosciences, Arlington Heights, IL) were used for
immunodetection. Quantification was performed by densitometric
scanning. The densitometry values were obtained in the linear
range of detection with these antibodies. These values were
normalized with respect to the values obtained with an anti-b-
tubulin antibody to correct for total protein content.
Immunostaining
For GFAP immunohistochemistry, sections were rinsed in PBS
and incubated in blocking solution (PBS/BSA/FBS/Tx-100)
followed by an overnight incubation at 4u with the primary
antibody: rabbit anti-GFAP (1/500) (Promega). Then, sections
were washed and incubated for 1 hour with the goat anti-rabbit
biotinylated antibody (1:400, Vector) and then another hour with
an avidin-biotin-peroxidase complex complex (ABC, 1:250,
Vector). The antibody staining was finally visualised with
diaminobenzidine (DAB, 0.05%, Sigma). Images were taken using
an Axioskop 2 plus microscope and a CCD camera (Coolsnap FX
color).
For immunofluorescence, immunostaining was carried out
following a standard procedure. Sections were incubated with
the primary antibody overnight at 4uC in a PB solution containing
BSA 1% and TritonX-100 1%. The following antibodies were
used: mouse anti-Myc, (1/100) (Hibridoma) and rabbit anti-fractin
(1/500) (BD Pharmingen). After washing with blocking solution 3
times, sections were incubated with donkey Alexa-conjugated
secondary antibodies (anti-rabbit, anti-mouse Alexa-Fluor 488/
555/633-conjugated) overnight at 4uC (1:1,000) (Molecular
Probes, Millipore). Finally, after washing with PB solution, sections
were incubated with DAPI (1/5,000) (Calbiochem) for 10 minutes.
Cell counting
Fractin- and reactive GFAP-positive cells were quantified on a
series of slices of dorsal and ventral dentate gyrus (DG) from 2
months-old wildtype and transgenic mice using an inverted
Axiovert200 Zeiss fluorescence microscope. Astrocytes were
considered reactive when they showed hypertrophy and a great
number of shorter GFAP-positive processes. The number of
positive cells for each marker was divided among each sections DG
volumen in order to obtain a cell density (cells/mm
3). The DG
area of each section was estimated delineating de border of the
granule cell layer on the same sections where cell numbers was
estimated, by using DAPI staining and a 5X objective. Data are
presented as mean cell density (cells/mm
3). All DG areas were
measured using Image J software (ImageJ, v. 1.33, NIH, Bethesda,
MD, USA, http://rsb.info.nih.gov/ij).
Density of mature granule neurons (Number of cells/mm3) and
myc-positive cells was analyzed through the application of a
physical-dissector method developed for confocal microscopy
(Zeiss LSM710), as described previously [25]. Briefly, the physical
dissector was applied to sections stained with DAPI and myc, so all
nuclei of mature neurons in the granule cell layer were counted
(excluding those nuclei resembling erythrocytes, if any, and the
immature cells, easily distinguishable because of its irregular
nuclear profiles and highly condensed cromatin). Data are
presented as cell density (cells/mm
3).
Novelty Suppressed Feeding test
Adult mice (three months) were weighed and food was removed
from the cage, although water remained available ad libitum.
Twenty-four hours later mice were transferred placed in a novel
arena with in the center a pre-weighed quantity of food pellets.
Each animal was placed in the corner of the testing area and the
latency to chew a food pellet (about 2 g) located in the center of
the arena, time spent feeding, and total food consumption were
Neurodegeneration of Dorsal and Ventral DG
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between 13:00 and 18:00 h.
Light/Dark Choice Test
Exploration of the light/dark chamber was measured using the
equipment from Med Associates Inc. The mouse is placed for
15 min in a box made of two compartments, one white and lit and
the other dark. Two parameters were recorded, the percent of
time spent in the dark compartment and the number of transitions
between compartments (crossings).
Statistical analysis
Data were analyzed using two-way ANOVA in dorsal and
ventral comparisons between wild-type and transgenic mice. To
compare GSK-3 levels and its phosphorylated status in wild-type
and GSK3b mice separately, we perform a t-test. All the analyses
were performed using SPSS for Windows version 17.0.
Results
GSK3b levels in ventral and dorsal DG
To examine whether there exist dorso-ventral differences in
GSK3b levels in wild-type mice, western blot analysis of dorsal
hippocampus and ventral hippocampus homogenates were
performed using antibodies that recognize inactive GSK-3b
(phosphorylated at serine 9) and with an antibody that recognize
GSK3b regardless of its phosphorylation state. Western blot
determination of the phosphorylated form of GSK3b revealed an
increase in the ratio phosphorylated/unphosphorylated forms in
ventral area compared with dorsal area in wild-type mice
(Figure 1). The main kinase able to phosphorylate inhibitory
GSK3 domains is AKT, thus we analyzed by western blot the
hippocampal levels of the active form of AKT that results from
phosphorylation on Ser473. Interestingly, and in good agreement
with GSK3b findings, AKT is more active ventrally than dorsally.
This resulted in a slight (although no statistically significant)
Figure 1. Western blots analysis of GSK3b, AKT and tau proteins in dDG and vDG from wild-type mice. (A) Representative western blots
showing GSK3b, phosphorylated GSK-3 (pSer9-GSK3b), AKT, phosphorylated AKT (pSer473-AKT), phosphorylated tau (pSer396/404-Tau), tau and actin
in homogenates from dorsal and ventral hippocampus of wild-type mice. Hippocampal extracts were prepared from animals aged 2 months. (B)
Histograms showing the densitometric quantification of samples shown in A. GSK3 and AKT ventral data are expressed in terms of the percentage of
signal respect to dorsal levels. Histograms showing tau levels represent phosphorylated tau (PHF-1)/total Tau (7.51). Solid bars, dorsal hippocampus;
open bars, ventral hippocampus. *P,0.05 versus dorsal hippocampus.
doi:10.1371/journal.pone.0027262.g001
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in the nervous system, as demonstrated by western blotting with
the PHF-1 antibody. These data strongly suggest that some
regional differences exist in the DG with a reduced ventral GSK3b
activity compared with dorsal area.
Transgenic GSK3b is overexpressed in ventral and dorsal
DG
The tTA transgene is under the control of the calcium/
calmodulin kinase IIa promoter allowing expression of transgenes
in forebrain neurons. To gain insight into which dentate gyrus
area is overexpressing transgenic GSK3b, we performed immu-
nofluorescence with anti-MYC antibody (transgenic GSK3b has a
myc epitope at its N-terminal end). Immunofluorescence analysis
of sagittal brain sections from GSK3b mice revealed intense
staining of the MYC-GSK3b transgene with the anti-myc
antibody in granular neurons from dDG and vDG (Fig. 2A).
Western-blot analysis was used to confirm that both hippocampal
areas show similar transgenic GSK3b levels. Probing protein
extracts with anti-GSK3b antibody demonstrated similar levels of
transgenic GSK3b (with a slight higher molecular weight due to
myc epitope) in both hippocampal areas (Fig. 2B–C). From these
experiments we therefore conclude that transgenic GSK3b levels
are similar in dDG and vDG. Then, we analyzed Ser9
phosphorylation of total GSK3b. Fig. 2B–C shows, as previously
observed in wild-type mice, an slight increase (although no
statistically significant) in the levels of inactive GSK3b in ventral
area. Tau phosphorylation in dorsal and ventral areas showed a
distribution similar to those found in wild-type mice.
Neurodegeneration is observed in dorsal DG, but not in
ventral DG
Since overexpression of GSK3b results in apoptotic neuronal
death in the dentate gyrus as shown in the initial characterization
Figure 2. Pattern of transgene expression in GSK3b mice. (A) Immunofluorescence in dDG and vDG hippocampal sections of GSK3b mice
performed with an antibody against MYC epitope. Arrows shown MYC-positive cells. (B) Representative western blots showing GSK3b,
phosphorylated GSK-3 (pSer9-GSK3b), phosphorylated tau (pSer396/404-Tau), tau and actin in homogenates from dorsal and ventral hippocampus of
GSK3b mice. Hippocampal extracts were prepared from animals aged 2 months. (C) Histograms showing the densitometric quantification of samples
shown in B. GSK3 data are expressed in terms of the percentage of signal respect to dorsal levels. Histograms showing tau levels represent
phosphorylated tau (PHF-1)/total tau (7.51). Solid bars, dorsal hippocampus; open bars, ventral hippocampus (n=6 dDG; n=7 vDG).
doi:10.1371/journal.pone.0027262.g002
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in DG of GSK-3b mice might also result in regional apoptosis. To
explore in a quantitative manner the incidence of neuronal
apoptosis of GSK3b mice, we performed fractin staining (fractin is
an actin fragment cleaved by caspase labeling dying cells). In good
agreement with previous findings, GSK-3 mice showed an
increase in the number of fractin-positive cells in the dDG (an
increase of 168630%. P,0.001, n=9, Fig. 3), while no a
significant difference in the number of fractin-positive cells was
detected in the vDG.
In view of this previous finding, we decided to test whether dDG
increased apoptosis results in a loss of granular neurons through
the application of a physical-dissector method in 2-months-old
GSK3b mice. As can be seen in Fig. 4 a significant decrease
(19.560.4%, p,0.001, n=6) in the number of granular neurons
was found in 2-months-old GSK3b dDG with respect to their
control littermates. We did not find that decrease in vDG.
Reactive astrogliosis often accompanies neuronal loss and serves
as a hallmark lesion for neurodegeneration. Thus, we next tested
whether the neuronal alterations triggered by overexpression of
Figure 3. Neural death in GSK3b mice. (A) dDG representative image of fractin positive cells (arrows) from GSK3b mice. DAPI staining in red is
also shown. (B) Quantification of the number of fractin positive neurons in dDG and vDG from wt (n=9) and GSK3b mice (n=11). A higher number of
fractin positive cells were found in dDG from GSK3b mice compared to wild-type mice. *P,0.001 versus wt animals.
doi:10.1371/journal.pone.0027262.g003
Figure 4. Stimates of total cell number in granule cell layer. Total neurons in 2-mounths old wt and GSK3b mice in dDG and vDG were
measured as described in Materials and methods. *P,0.05 versus wt animals.
doi:10.1371/journal.pone.0027262.g004
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remarkable increase in astrogliosis was quite evident in hippo-
campal dDG (an increase of 177.8610.5% compared with wild-
type mice , p,0.001, n=11) as shown by immunohistochemistry
performed with an antibody raised against GFAP, but not in vDG
of GSK3b mice. Together, these results indicate that the
neurodegeneration occurs in mice overexpressing GSK3b mainly
in hippocampal dDG.
We have reported that GSK3b mice present a severe atrophy of
total DG, suggesting an important neurodegeneration [7]. To
characterize this neurodegeneration, we have previously analyzed
thionine-staining in brain sections from two year-old GSK3b mice.
Those studies showed a clear reduction in the size of the DG in
GSK3b mice when compared to the wt mice. However, we used
the entire DG for quantification analysis and a regional study was
not performed. When we carried out that kind of analysis a
substantial decrease in the dDG of the hippocampus of GSK3b
mice was observed. A volumetric analysis of thionine-stained brain
sections (Figure 6) revealed that, as compared to wild-type mice, 2-
year-old GSK3b mice exhibited an 40.467.06% (P,0.05, n=3)
decrease in dDG volume while vDG was almost unchanged (a
decrease of 1.0262.96%; P,0.6, n=3). These data indicate that
Figure 5. Reactive astrocytosis in dDG compared to vDG in wild-type and GSK3b mice. Immunohistochemistry in hippocampal sections of
wild-type (wt) and GSK3b mice performed with an antibodieys against GFAP. Quantification of the number of reactive astrocytes in 2-months-old
wild-type (n=9, wt) or GSK3b mice (n=11). *P,0.001 versus wt animals.
doi:10.1371/journal.pone.0027262.g005
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dorsal area.
Behavioral consequences of GSK3b overexpression
We have previously demonstrated that an increase in GSK3
activity in the hippocampus is enough to elicit a deficit in spatial
learning in the Morris water maze [19]. Learning deficits in
GSK3b mice were also evidenced in the object recognition test
[20]. These data confirm that hippocampal functions related with
dorsal hippocampus are altered in GSK3b mice and those
alterations are already present in one-month old animals [20].
To evaluate whether GSK3b overexpression also alter functions
related with ventral areas, mice were tested on two tests of anxiety-
like behavior: light/dark box and novelty suppressed feeding test
(Figure 7). In the light/dark test, GSK3b mice did not show
differences respect to wild-type mice in total crossings (T-test,
t=1,395; p=0.193) or in the amount of time spent in the dark
compartment (T-test, t=20.795; p=0.445). Similar findings were
observed in the novelty suppressed feeding test (Figure 7). Thus,
latency to feed in the home cage and amount of food consumed
were not different between both groups which suggest again no
alterations in motivational factors. Interestingly, no differences in
the weight loss during food restriction among transgenic and wild-
type mice were detected. These data, with the previously described
no differences in the open field test, in terms of total horizontal and
vertical activities, time spent in movement, time spent in centre vs.
periphery, or stereotypic movements [19] demonstrate that
GSK3b mice do not have altered anxiety-like behavior.
Discussion
The main finding of the current study was to demonstrate that
dorsal dentate gyrus is more susceptible to degeneration than
ventral area in response to an increase in GSK3b levels, regarding
the pattern of transgene expression driven by the CamKIIa
promoter, with similar expression in all the hippocampal DG
neurons. That conclusion is supported by the following observa-
tions: (i) a reduction in the number of granular neurons is observed
in dDG of GSK3b mice compared with ventral area; (ii) neuronal
death is increased in dDG of GSK3b mice; (iii) overexpression of
GSK3b in both DG areas was accompanied by reactive
astrocytosis only in the dorsal area; iv) in good agreement,
anxiety-like behavior (measured in light/dark box and novelty
suppressed feeding tests) is not altered indicating that behavior
alterations related with ventral area were not found although a
cognitive deficit, related with dorsal areas, is present.
Deregulation of GSK3 has been linked to several prevalent
neuropathological conditions. These include bipolar mood
disorder [4], schizophrenia [5], diseases like Huntington’s disease
[6], frontotemporal dementia with parkinsonism linked to
chromosome 17 [7] and Alzheimer disease [8]. Therefore, the
data reported here on regional consequences of increased GSK3
levels in the DG may have implications in many disease conditions.
Our results show that increased GSK3 levels induces a severe
pathology in the hippocampus thus strengthening the hypothesis
that GSK3 deregulation may contribute to neurodegeneration.
However, important differences seem to exist among neurons.
Figure 6. dDG and vDG volume of granule cell layer in old GSK3b mice. Representative sagittal sections from 18-month-old wild-type (A)
and GSK3b mice (B) thionine stained samples used to measured volumetric quantifications. (C) Volumetric quantification of the atrophy was
determined as described in Material and Methods. *P,0.05 versus wt animals.
doi:10.1371/journal.pone.0027262.g006
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others seem to survive. Thus, dDG granular neurons undergo
apoptotic death (measured as an increase in the number of fractin-
positive cells), while vDG neurons do not suffer that processes and
survive. The results reported here are indicative of the effects of
increased GSK3b levels and, to some extent, they may have
implications when considering the potential side effects and the
potential therapeutic efficacy of chronic administration of potent
and selective GSK-3 inhibitors that are currently under develop-
ment for treatment of chronic conditions such as Alzheimer’s
disease and mood disorders [13,14].
These findings raise the question of how GSK3b overexpression
causes dDG degeneration while ventral area seems to be
protected. Both regions differ not only in gene expression but
also in neuronal connectivity [15]. Taking into account that
GSK3b is an enzyme with wide effects on neuronal metabolism,
including gene expression [2] neuronal cytoskeleton, plasticity,
intracellular transport and neuronal survival, [26] our study
suggests that transduction pathways modulating GSK3 are
different in both areas.
It is well established that GSK3b activity is inactivated by
phosphorylation at Ser9, mainly via AKT, and inhibition of
GSK3b is a common event in neuroprotection by different
survival factors [2]. We found that GSK3b protein levels were
similar in both areas. However, the phosphorylation of AKT at
Ser473, which represents its activation, increased in ventral areas
and Ser9 phosphorylation of GSK3b was found to be high also in
ventral areas. In good correlation, our data seem also to suggest
that tau protein phosphorylation, one of the main GSK3
substrates, is slightly less phophorylated in ventral area than in
dorsal one. Differences in tau phosphorylation are likely not higher
because Ser396/404 epitope is phosphorylated not only by
GSK3b but also by other kinases as mitogen-activated protein
kinases ERK2, c-Jun N-terminal kinase and P38 [27]. Thus,
Figure 7. Tests of anxiety-like behavior. Histograms showing the performance of 10-week-old wild-type (wt, white bars, n=6) or GSK3b mice
(black bars, n=6) in the novelty suppressed feeding test and the white-black box. (A–B) Light/dark box: (A) Percent of time spent in the dark
compartment (B) Number of transitions between the two compartments made by wt and GSK3b mice. (C–F) Novelty supressed feeding test: (C) Wild-
type and transgenic mice lost a similar body weight during the 24 h of food restriction. Twenty-four hours after food restriction, mice were
transferred to the testing room, placed in a novel arena with in the center a pre-weighed quantity of food pellets. Each subject was placed in the
corner of the testing area, and the latency to feed (D), time spent feeding (E), and total food consumption (F) were recorded over 10 min. No
significant differences were observed.
doi:10.1371/journal.pone.0027262.g007
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be suggested that ventral hippocampus withstands an increase of
GSK3 better than dorsal hippocampus. However, further studies
are required to specify the mechanisms responsible for those
differences as well as the factors making the dDG particularly
sensitive to GSK3b mediated apoptosis.
Taking into account our results it is tempting to speculate that
some differences may exist among posterior and anterior human
DG (which correspond to dorsal and ventral DG in mice [15]) in
relation with GSK3. Aberrantly increased GSK3 activity is
believed to play a key role in the pathogenesis of mood disorders
[2] and in neurodegenerative processes as AD [8]. Focusing in
AD, GSK3 has been proposed as the main kinase able to
phosphorylate tau aberrantly [28,29,30]. Hyperphosphorylated
tau does not appear in human dentate gyrus until late stages of
Alzheimer’s disease [31]. However, mini mental tests demonstrate
that cognitive and memory deficits occur in early stages showing
that hippocampus is actually altered. Besides, loss of layer II
entorhinal neurons occurs in early AD stages [32] suggesting that
all these deep changes in the entorhinal input has to have a big
impact on it. In fact, although no plaques, tangles or neuronal
death appear at early AD stages it has been proposed a partial
‘‘disconnection’’ of the human dentate gyrus in AD [31]. Although
actually it is merely speculative to propose that posterior
hippocampal human regions are involved in memory and learning
processes, while anterior areas are related with emotional and
anxiety processes, as it occurs in mouse, functional differences of
the anterior versus posterior hippocampus have been reported
[33,34].
In summary, our results demonstrate that dorsal and ventral
dentate gyrus do not conduct in a similar way in an animal model
overexpressing GSK3b. Thus, the dorsal area is more vulnerable
than the ventral one. These results may help to understand partly
why in some neurodegenerative process the cognitive and
behavior alterations do not come out at the same time. From a
more general perspective, our study also suggests that the DG
should not be studied as a homogeneous region and studies
focused in neurodegeneration should study dorsal and ventral
areas.
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